NASDAQ · Financial Statements

Klotho Neurosciences, Inc. (KLTO) Financial Statements

$0.38 NASDAQ: KLTO Market Cap $20.08M

Klotho Neurosciences, Inc. most recently reported annual revenue of $0, a net loss of $11.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Klotho Neurosciences, Inc.: net profit was positive in 0 of 5 reported years; the most recent year shows a net loss of $11.0M.

Income Statement — 5 Years (USD millions)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Expenses$1.0M$1.0M$1.0M$6.0M$7.0M
Operating Profit$-1.0M$-1.0M$-1.0M$-6.0M$-7.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%
Other Income$0$0$0$-1.0M$-3.0M
Interest$0$0$0$0$2.0M
Depreciation$0$0$0$0$0
Profit Before Tax$-1.0M$-1.0M$-1.0M$-6.0M$-11.0M
Tax$0$0$0$0$0
Net Profit$-1.0M$-1.0M$-1.0M$-6.0M$-11.0M
EPS$0.00$0.00$0.00$-0.32$-0.22
Dividend Payout0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

MetricJun '23Sep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$0
Operating Expenses$0$0$0$1.0M$0$3.0M$2.0M$2.0M$2.0M$2.0M$2.0M$10.0M
Operating Profit$0$0$0$-1.0M$0$-3.0M$-2.0M$-2.0M$-2.0M$-2.0M$-2.0M$-10.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%
Interest$0$0$0$0$0$0$0$1.0M$2.0M$1.0M$0$0
Profit Before Tax$0$0$0$-1.0M$0$-3.0M$-2.0M$-2.0M$-4.0M$-3.0M$-1.0M$-14.0M
Tax$0$0$0$0$0$0$0$0$0$0$0$0
Net Profit$0$0$0$-1.0M$0$-3.0M$-2.0M$-2.0M$-4.0M$-3.0M$-1.0M$-14.0M
EPS$-0.02$0.00$-0.01$0.00$-0.03$-0.18$-0.08$-0.08$-0.12$-0.05$-0.02$-0.15

Over the 5 years reported for Klotho Neurosciences, Inc., cash stood at $7.0M in the latest year, shareholders' equity was $0.

Balance Sheet — 5 Years (USD millions)

Metric20212022202320242025
Total Assets$1.0M$3.0M$2.0M$2.0M$10.0M
Current Assets$0$0$0$0$7.0M
Cash$0$0$0$0$7.0M
Inventory$0$0$0$0$0
Receivables$0$0$0$0$0
Fixed Assets$0$0$0$0$0
Capital Work in Progress$0$0$0$0$0
Investments$0$0$0$0$0
Other Assets$0$0$0$0$0
Total Liabilities$0$1.0M$2.0M$1.0M$0
Current Liabilities$0$1.0M$2.0M$1.0M$0
Borrowings$0$1.0M$1.0M$0$0
Other Liabilities$0$0$0$1.0M$0
Equity$0$0$0$0$0
Reserves$1.0M$1.0M$1.0M$1.0M$9.0M

For Klotho Neurosciences, Inc., operating cash flow was positive in 0 of 5 reported years; free cash flow in the latest year was negative at $6.0M; free cash flow was positive in 0 of 5 years.

Cash Flow Statement — 5 Years (USD millions)

Metric20212022202320242025
Operating Cash Flow$0$-1.0M$0$-3.0M$-6.0M
Investing Cash Flow$0$0$0$0$0
Financing Cash Flow$0$0$0$1.0M$0
Net Cash Flow$0$0$0$0$7.0M
Free Cash Flow$0$-1.0M$0$-3.0M$-6.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.08
EV / EBITDA-0.67
FCF Yield-47.81%
Quick Ratio19.74
Interest Coverage-5.13
Return 1Y—
Return 3Y—
Return 5Y—

Klotho Neurosciences, Inc. (KLTO) financials — frequently asked questions

What is Klotho Neurosciences, Inc.'s annual revenue?

Klotho Neurosciences, Inc. (KLTO) reported annual revenue of $0 in its most recent fiscal year.

What is Klotho Neurosciences, Inc.'s net profit?

Klotho Neurosciences, Inc. (KLTO) reported a net loss of $11.0M in its most recent fiscal year.

What is KLTO EV/EBITDA?

Klotho Neurosciences, Inc.'s enterprise value to EBITDA (EV/EBITDA) ratio is -0.67. A negative value means EBITDA was negative over the period, so the ratio is not a meaningful valuation measure.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
KLTO Overview KLTO Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.